Published in Vaccine Weekly, May 26th, 2010
For the quarter ended March 31, 2010, Bioject reported revenues of $1.2 million compared to $2.0 million reported in the comparable year-ago quarter. Product sales for the first quarter of 2010 were $1.1 million compared to $1.9 million in the year-ago quarter. License and technology fees for the first quarter of 2010 were $96,000 compared to $128,000 in the comparable year ago period. Operating expenses for the first quarter of 2010 were $1.7 million compared to $2.2 million in the comparable 2009...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.